Professor Walsh is one of Ireland’s most experienced diagnostics entrepreneurs and now holds the post of Bio-Innovator in Residence with Dublin City University. He is currently executive director and CSO of Trinity Biotech Plc (NASDAQ: TRIB) an Irish Diagnostics company and executive chairman of Biosensia Ltd., an Irish Point of Care Diagnostics Company. He is also an investor in and director of a number of early stage Diagnostic companies, including Enzolve Technologies Ltd. (Paediatric testing), Epona Biotech (Animal Haematology), Crescent Diagnostics Ltd., (Bone Health). Previously Prof. Walsh was Executive Chairman of GenCell Biosystems Ltd., acquired by Becton Dickenson in 2014 and CEO of Stokes Bio Ltd., acquired by Life Technologies in 2010, non- executive director at PuriCore Plc. (LSE: PURI) and Managing Director of Cambridge Diagnostics Ltd. a wholly owned subsidiary of Alere Inc. Prof. Walsh bring a wealth of commercial and industry expertise to the company.
Bill is an Australian entrepreneur, venture capital investor, diplomat, author and speaker with a distinguished record in the areas of business, development and community activism. Bill is co-founder of the CoderDojo movement, a free global network formed to assist young people to learn how to computer program and Founder of WeForest, a global movement dedicated to planting trees and which now has seen 5 million trees planted around the world.
He is also the European venture partner for SOSV a $200m international investment fund and is currently running a Synthetic Biology Accelerator Program, IndieBio, in Cork, focusing on entrepreneurs building technologies in or around the field of Synthetic biology.
Previously, Bill co-founded XING, a pioneering business social networking platform in 2003 and served as COO of Davnet a telecommunications carrier that went public in the late 90’s. Bill serves as a special diplomatic envoy for St Kitt’s and Nevis, with an emphasis on sustainable development and the environment. Author of three books, he is a regular speaker at many events and venues such as The London School of Economics, The World Economic Forum, The Globe Forum in Sweden, The House of Commons and TED.
Mr. Walsh worked for several years in San Francisco working for investment bank, Volpe Welty, as a Research Associate and Prudential Volpe as an Equity Research Analyst covering the Enterprise Software space. As an Analyst, Frank was involved in several technology IPOs, Secondaries and PIPEs (Private Investment in Public Equities). He was also responsible for the firm’s thematic research and publication in the enterprise software space.
Between his two roles in San Francisco, Frank worked as a Joint Venture Business Manager for Millicom International Cellular in Luxembourg. Millicom is a publicly traded company that develops and operates cellular telephone networks in developing countries.
Following his return to Ireland in 1998 Frank founded two companies, both of which operated successfully and were ultimately sold. Firstly, Technology Research Group which provided research analysis and valuation services to Irish technology and investment companies/funds was acquired by a start-up US Venture Capital Company to spear-head its operations in Ireland.
Declan is CEO at Maywentee Ltd. He is an engineer and entrepreneur based in Ireland with extensive international experience in technology companies. He was co-founder and President of Northstar Systems Inc based in Silicon Valley, Taiwan and China and spent considerable time in the USA and Asia. He was CEO of Firecomms, a high tech compound semiconductor company spun out from Ireland’s Tyndall National Institute. Firecomms was acquired by a Chinese corporation ZJY of Zhejiang in 2010. He was CEO of HeartSine Inc. a Defibrillator company with HQ in Pennsylvania. HeartSine sold products in 70 countries and was acquired by Physio-Control, Inc. in October 2015 and subsequently acquired by Stryker Corporation (NYSE: SYK) in April 2016. Declan is entrepreneur in residence at Tyndall National Institute and is a Non-exec director, investor and advisor to several technology companies.
Prof. Roberts is Professor of Obstetrics and Gynecology and Epidemiology and Clinical and Translational Research at the University of Pittsburgh. His research includes fundamental, clinical and health services approaches to the understanding and management of adverse pregnancy outcomes. He led a NIH RCT (10,000 women) of antioxidant vitamins to prevent preeclampsia. He was the recipient of lifetime achievement awards by the International Society for the Study of Hypertension in Pregnancy and the SGI and the 2008 Preeclampsia Foundation Hope Award for Lifetime Achievement. He has served or serves on the editorial boards of journals including, Placenta, Journal of Clinical Endocrinology, Metabolism and Hypertension. He has been on scientific review boards of the NIH, the CIHR, the FDA and the March of Dimes. He was the chair of the NICHD Maternal Fetal Medicine Network from 1990 –1999 and is past president of the Perinatal Research Society, the North American Society for the Study of Hypertension in Pregnancy, the Society of Gynecological Investigation and the International Society for the Study of Hypertension in Pregnancy. Roberts was formally admitted to fellowship ad eundem of the Royal College of Obstetricians and Gynaecologists in September of 2000. He has been elected to membership in Institute of Medicine of the National Academy of Sciences. He has also received mentoring awards from the NICHD and the Society of Gynecological Investigation
Brian Rappold is the Director of Mass Spectrometry at LabCorp. He currently serves as the clinical chemistry chair for the American Society for Mass Spectrometry as well as on the scientific committees for endocrinology and small molecule analysis/toxicology for Mass Spectrometry: Applications to the Clinical Laboratory (MSACL). He has published scientific articles and presented his research at international conventions on topics including hydrophilic interaction liquid chromatography for bio-analysis, multiplexed mass spectrometric detection of amino acidopathies, and the origins and solutions of ion suppression in electrospray ionization. He is a recognized expert in the field of method development and validation of mass spectrometry assays for clinical diagnostic use, teaching courses on the topic at numerous scientific conferences.
Rappold also co-authored the chapter “Development and Validation of Small Molecule Analytes By Liquid Chromatography-Tandem Mass Spectrometry” in the 6th edition of the Tietz Textbook of Clinical Chemistry and Molecular Diagnostics (2016). This classic chemistry reference is considered the most current and authoritative guidance on selecting, performing, and evaluating the results of new and established laboratory tests.
Stafford O’Kelly, was President of Abbott Molecular from 2007-2012. Prior to this he held several senior positions within Abbot including; Vice President, Latin America/Canada Operations; Division Vice President Finance, Abbott International, Division; Vice President and Controller, Ross Products Division (now Abbott Nutrition); and Vice President, Finance, TAP Pharmaceuticals, Inc.
In April 2015, he became a founder of Altan Pharma Ltd., which acquired the GES group of companies which operate out of Spain, for €87m.
Mr. O’Kelly serves on the boards of Youth Conservation Corps, Inc., and the Clara Abbott Foundation